Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

BACKGROUND: Alzheimer’s disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) followed by y-secretase. Verubecestat is an oral BACE-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Egan, Michael F., Kost, James, Tariot, Pierre N., Aisen, Paul S., Cummings, Jeffrey L., Vellas, Bruno, Sur, Cyrille, Mukai, Yuki, Voss, Tiffini, Furtek, Christine, Mahoney, Erin, Mozley, Lyn Harper, Vandenberghe, Rik, Mo, Yi, Michelson, David
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6776074/
https://ncbi.nlm.nih.gov/pubmed/29719179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1706441
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares